top of page

Cholesterol: Friend, Foe, or Both?


Yellow fatty compound and red blood cells in motion against a blurred dark background, creating a dynamic, scientific atmosphere.

Authors: Annabella Irani-Fey, Tripura Reddy, and Rihaan Shah


Mentor: Dr. Liam Barrett. Dr. Barrett is currently pursuing a DPhil in medical science at the University of Oxford.


Abstract

This review explores a simple question with a nuanced answer: is cholesterol good or bad for you. Cholesterol is essential for human biology, yet it also contributes to atherosclerosis and cardiovascular disease. We bring together evidence on cholesterol’s normal roles, how it leads to plaque formation, how to assess risk, and what helps prevent heart attacks and strokes.

 

Cholesterol supports cell membranes, steroid hormone synthesis, vitamin D production, and bile acids. High density lipoprotein helps remove extra cholesterol from the bloodstream. Problems arise when low density lipoprotein and related particles stay high for years. These particles can enter the artery wall, become oxidized, trigger inflammation, and form plaques that may rupture and cause clotting. This process underlies many heart attacks and strokes. Risk tools such as QRISK3, the ASCVD Pooled Cohort Equations, and the Framingham Risk Score combine cholesterol with other factors to estimate 10-year risk and guide prevention.

 

Prevention draws on lifestyle and medications. Mediterranean and plant-forward eating patterns, regular activity, weight control, and quitting smoking improve lipid profiles. Statins are first line for lowering LDL cholesterol and reducing clinical events. Ezetimibe and newer options are useful when targets are not reached or when statins are not tolerated. Policies such as industrial trans-fat bans and population risk checks can lower risk at the community level.

 

Cholesterol itself is neither simply good nor bad. Its impact depends on which particles carry it, how high levels are, and how long they remain elevated, alongside other health factors. A practical mix of risk assessment, lifestyle change, and appropriate therapy offers the best protection.


Introduction

Cholesterol is a waxy, fat-like substance found in every cell. It stabilizes membranes, helps organize signalling, and is the starting material for steroid hormones. With sunlight, the skin converts a cholesterol precursor into vitamin D. The liver uses cholesterol to make bile acids that help digest fat. Because cholesterol does not dissolve in water, the body transports it in blood inside lipoprotein particles. The main ones are low density lipoproteins, very low-density lipoproteins and their remnants, and high-density lipoproteins. In everyday language LDL is called the “bad” cholesterol and HDL the “good,” but a clearer way to explain it is that LDL and other apolipoprotein B particles deliver cholesterol to tissues, while HDL helps carry excess cholesterol back to the liver.

 

Cardiovascular diseases are the leading cause of death worldwide [1]. Atherosclerosis, the disease of the artery wall that underlies most heart attacks and many strokes, is closely linked to long term exposure to LDL cholesterol and related particles [2]. Even with better treatments, the burden remains large. This review keeps both sides of the story. First, it describes the useful roles cholesterol plays. Then it explains how atherosclerosis develops and why that leads to heart disease and stroke. It next looks at clinical tools that combine cholesterol with other factors to estimate a person’s risk. Finally, it discusses management, starting with diet and lifestyle and then medications, and steps back to look at public health policies. The goal is a practical summary that patients and clinicians can apply.


Literature Review

Biochemical

Research question 1: What essential and harmful roles does cholesterol have in the body.

Cholesterol is a core building block for life. It keeps membranes stable yet flexible, supports signalling in lipid rafts, and is the precursor for estrogen, testosterone, and cortisol. With sunlight, skin converts a cholesterol precursor to vitamin D. The liver turns cholesterol into bile acids that help absorb dietary fat. In the nervous system cholesterol helps make myelin, which insulates nerves and allows fast conduction. These are the “friend” roles.

 

The “foe” side appears when atherogenic particles remain high for years. A large body of genetic, epidemiologic, and clinical trial evidence shows that higher lifelong exposure to LDL cholesterol raises the risk of atherosclerotic cardiovascular disease, and that lowering LDL reduces events in a dose dependent way [2]. Diets high in saturated fat and especially industrial trans fats tend to raise LDL cholesterol, while eating patterns rich in unsaturated fats and fiber help lower it. Regular aerobic activity tends to raise HDL cholesterol modestly and improves insulin sensitivity, while smoking lowers HDL and injures the endothelium that lines arteries [16,17,21].


Research question 2: How does cholesterol cause atherosclerosis, and how does it progress to heart disease and stroke.

Atherosclerosis often begins early in life and develops over decades. At sites of disturbed blood flow, LDL particles cross the endothelium, bind to proteoglycans in the intima, and undergo oxidative and enzymatic changes. Modified lipoproteins attract monocytes that become macrophages; these take up cholesterol and form foam cells. Fatty streaks are the first visible sign of the disease [3–6,36]. Over time, smooth muscle cells migrate and produce collagen that forms a fibrous cap over a lipid rich core. When inflammation is high and dead cells are not cleared well, the cap can thin. Thin capped plaques are considered vulnerable. If the cap ruptures, blood is exposed to plaque contents and a clot can form, which may block the artery and cause a myocardial infarction or an ischemic stroke [5–7,23,37,38,39].

 

Inflammation adds to the story. High sensitivity C reactive protein predicts first cardiovascular events even after LDL is accounted for, which supports the idea that systemic inflammation provides added risk information [7]. Treatment changes plaque biology too. Intensive LDL lowering with statins reduces lipid content and inflammation inside plaques and often increases calcium density, a pattern that is consistent with greater stability even if a calcium score rises on imaging [22]. Coronary artery calcium scoring also tracks future risk at the population level [20].


Clinical

Research question 3: What tools are used to assess the risk of cholesterol-related diseases.

Absolute benefit from therapy depends on absolute risk, so clinicians use risk calculators that mix cholesterol with other factors to estimate 10-year risk.

QRISK3 is based on large UK primary care datasets and includes age, sex, blood pressure, smoking, diabetes, total and HDL cholesterol, and several added clinical conditions such as chronic kidney disease, migraine, severe mental illness, and steroid use [8]. In the United States, the ASCVD Pooled Cohort Equations estimate risk of nonfatal myocardial infarction, coronary death, or stroke using total cholesterol, HDL cholesterol, blood pressure, diabetes, smoking, sex, and race [9]. The Framingham Risk Score remains a general tool that predicts 10-year cardiovascular risk using the classic factors including lipids [10]. In selected people, coronary artery calcium imaging can reclassify risk. Results in statin users need careful interpretation because statins may increase calcium density as plaques stabilize [20,22].

 

These tools do not capture everything, but they link lab results to outcomes and help with shared decisions about when to intensify lifestyle changes, start a statin, or add a second agent.

 

Research question 4: What pharmacological treatments are available to control cholesterol levels.

Statins are first line. They reduce hepatic cholesterol synthesis, increase LDL receptors, and lower LDL cholesterol in the bloodstream. A pooled analysis of randomized trials showed that statins reduce coronary events compared with placebo, and that benefit tracks with the size of the LDL reduction achieved [11]. Statins also tend to stabilize plaques [22].

 

When targets are not reached or when statins are not tolerated, other agents can help. Ezetimibe lowers LDL by reducing intestinal absorption of cholesterol and is often added to a statin [30]. Fibrates mainly lower triglycerides and are helpful in severe hypertriglyceridemia, though their benefit for cardiovascular prevention is less consistent. Niacin raises HDL and lowers triglycerides but did not improve outcomes when added to intensive statin therapy and often causes side effects, so routine use has decreased. Newer options extend choices. Adding a PCSK9 inhibitor on top of statins lowers LDL substantially and reduces events in high-risk patients [28,29]. Bempedoic acid lowered LDL and reduced cardiovascular events in statin intolerant patients [31]. Inclisiran, an siRNA that reduces hepatic PCSK9 synthesis, provides sustained LDL reductions with infrequent dosing; outcome data are pending but LDL lowering is consistent across trials [32]. The practical idea is simple. For most people at elevated absolute risk, start with a statin. If more LDL reduction is needed, add ezetimibe, and consider other options for very high risk or statin intolerance.


Nutrition and Public Health

Research question 5: What is the role of dietary, non-pharmacological interventions.

Lifestyle change is the foundation and works with medications rather than replacing them. The focus has shifted from “low fat” in general to dietary patterns and fat quality.

 

Mediterranean style eating, rich in vegetables, fruits, whole grains, legumes, nuts, fish, and olive oil, reduces cardiovascular risk and can slow measures of atherosclerosis progression compared with low fat diets [24,13]. Vegetarian and vegan diets lowered LDL cholesterol, total cholesterol, and apolipoprotein B in randomized trials, with little change in triglycerides [14]. In people with or at high cardiovascular risk, plant-based patterns also improved BMI and HbA1c along with LDL [15]. The Portfolio diet, which combines plant sterols, viscous fiber, soy protein, and nuts, lowered LDL by about 17 to 30 percent in controlled feeding studies [25]. Soluble fibers such as oats and psyllium produce small but meaningful LDL reductions [26].

 

What replaces saturated fat matters. Replacing it with polyunsaturated fat lowers LDL and improves the total to HDL cholesterol ratio. Replacing it with refined starch or sugar does not help [17,27]. Industrial trans fats raise LDL and lower HDL and increase cardiovascular risk. Removing them from the food supply has been a major policy success [16].

 

Weight, activity, and smoking all influence lipids. Losing weight helps lower triglycerides and can improve LDL and HDL. Regular aerobic exercise modestly raises HDL and improves insulin sensitivity [21]. Smoking cessation improves HDL and reduces oxidative stress that damages the endothelium.

 

Research question 6: How have public health policies evolved and changed clinical practice or outcomes.

Policy can shift risk across a whole population. Denmark’s national restriction on industrial trans fats and county level bans in parts of the United States were associated with reductions in cardiovascular events, in line with the expected lipid effects of removing trans fats from foods [33,34,16]. In England, the NHS Health Check program increased detection of high cholesterol and other risk factors and supported targeted statin use when implemented well [18]. Global patterns show mean non-HDL cholesterol has fallen in many high-income regions but risen in others, which calls for tailored strategies that match local diets and access to care [35].


Discussion

Cholesterol's double role: friend and foe

Cholesterol is essential inside cells, in hormones, and in bile acids. That is the friend side. The foe side reflects what happens when LDL and other apolipoprotein B particles are high for years and become trapped in artery walls. Modified lipoproteins drive inflammation, foam cell formation, and plaque growth. Vulnerable plaques can rupture and trigger a clot, causing a heart attack or stroke [2–7,23]. This twin story explains why simply labeling cholesterol as good or bad is not helpful. Context and balance matter.

 

From molecule to disease: the atherosclerotic pathway

Atherosclerosis starts quietly—lipoprotein entry and retention in the arterial wall, oxidative modification, macrophage recruitment, and foam cell formation—long before symptoms appear. Over time, plaques grow and may become vulnerable to rupture. When a plaque ruptures or erodes, a thrombus can form and block blood flow. Inflammation adds risk, with high sensitivity C reactive protein giving extra prognostic information beyond LDL alone [7]. These mechanisms support early identification and treatment: reduce the burden of atherogenic particles, calm inflammation, and stabilize plaques [22,20].

 

Risk, treatment, and lifestyle: preventing cholesterol-related disease

Risk calculators such as QRISK3, the ASCVD Pooled Cohort Equations, and the Framingham Risk Score connect lab numbers and clinical features to a concrete 10 year risk and a plan [8–10]. They are guides rather than rules, but they help match therapy intensity to absolute risk and avoid overtreatment in low-risk people. For many patients at raised risk, statins offer a reliable way to reduce LDL and prevent events, with add on options when more lowering is needed or when statins are not tolerated [11,28–32]. Lifestyle remains the bedrock. Mediterranean and plant forward patterns are reasonable starting points and can be adapted to culture and budget. Exercise adds benefit even if the scale moves slowly. For people at higher absolute risk, medication is often needed as well. Together they work better than either alone.

 

Shifting guidelines and public messages: what changed and why

Public advice has moved from “low fat everything” to a more nuanced emphasis on diet quality and fat replacement. Replacing saturated fat with polyunsaturated fat helps. Removing industrial trans fats has delivered measurable health gains [16,33,34]. Screening programs that identify and treat high risk individuals add further benefit [18]. Continued attention to equitable access is important so improvements reach underserved groups. With obesity and diet related illness still common, prevention efforts need to stay active.

 

Final thoughts and future directions

Cholesterol is both friend and foe. The practical takeaway is simple. Assess absolute risk using a recognized tool. Prioritize durable LDL reduction when risk is elevated, usually with statins first line and add-ons as needed. Support lifestyle changes that patients can sustain. Advocate for policies that make healthy choices easier. Earlier action across the life course should yield the biggest gains.


Conclusion

Cholesterol is vital for normal physiology but becomes hazardous when LDL rich particles stay high and get trapped in artery walls. Strong evidence shows that lowering LDL cholesterol reduces atherosclerotic events. Risk calculators help target preventive therapy. Statins remain first line, with ezetimibe and other options when needed. Lifestyle change is the foundation and works alongside medication. Policies that improve diet quality and support risk detection can reduce events at the population level. Cholesterol is neither purely good nor purely bad. Its health impact depends on the particles that carry it, how high they are, and how long they remain elevated, together with other risk factors.


References

  1. World Health Organization. (2025, July 31). Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

  2. Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease: Evidence from genetic, epidemiologic, and clinical studies. European Heart Journal, 38(32), 2459–2472. https://doi.org/10.1093/eurheartj/ehx144

  3. Insull, W., Jr. (2009). The pathology of atherosclerosis: Plaque development and plaque responses to medical treatment. The American Journal of Medicine, 122(1 Suppl), S3–S14.

  4. Kakadiya, J. (2009). Causes, symptoms, pathophysiology and diagnosis of atherosclerosis: A review. Pharmacologyonline, 3, 420–442.

  5. Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014). Mechanisms of plaque formation and rupture. Circulation Research, 114(12), 1852–1866.

  6. Otsuka, F., Kramer, M. C., Woudstra, P., et al. (2015). Natural progression of atherosclerosis from pathologic intimal thickening to late fibroatheroma in human coronary arteries. Atherosclerosis, 241(2), 772–782. https://doi.org/10.1016/j.atherosclerosis.2015.05.011

  7. Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. The New England Journal of Medicine, 347(20), 1557–1565.

  8. Hippisley-Cox, J., Coupland, C., & Brindle, P. (2017). Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease. BMJ, 357, j2099. https://doi.org/10.1136/bmj.j2099

  9. Goff, D. C., Jr., Lloyd-Jones, D. M., Bennett, G., et al. (2014). 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Journal of the American College of Cardiology, 63(25 Pt B), 2935–2959.

  10. D’Agostino, R. B., Sr., Vasan, R. S., Pencina, M. J., et al. (2008). General cardiovascular risk profile for use in primary care. Circulation, 117(6), 743–753.

  11. Pignone, M., Phillips, C. J., & Atkins, D. (2000). Screening and treating adults for lipid disorders. The American Journal of Medicine, 109(6), 491–500.

  12. Pahwa, R., & Jialal, I. (2023). Atherosclerosis. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK507799/

  13. Jimenez-Torres, J., Alcalá-Díaz, J. F., Torres-Peña, J. D., et al. (2021). Mediterranean diet reduces atherosclerosis progression in coronary heart disease: CORDIOPREV randomized controlled trial. Stroke, 52(11), 3440–3449. https://doi.org/10.1161/STROKEAHA.120.033214

  14. Koch, C. A., Kjeldsen, E. W., & Frikke-Schmidt, R. (2023). Vegetarian or vegan diets and blood lipids: A meta-analysis of randomized trials. European Heart Journal, 44(28), 2609–2623. https://doi.org/10.1093/eurheartj/ehad211

  15. Wang, T., Kroeger, C. M., Cassidy, S., Mitra, S., Ribeiro, R. V., Jose, S., et al. (2023). Vegetarian dietary patterns and cardiometabolic risk in people with or at high risk of cardiovascular disease. JAMA Network Open, 6(7), e2325658. https://doi.org/10.1001/jamanetworkopen.2023.25658

  16. Mozaffarian, D., Katan, M. B., Ascherio, A., Stampfer, M. J., & Willett, W. C. (2006). Trans fatty acids and cardiovascular disease. The New England Journal of Medicine, 354(15), 1601–1613.

  17. LaRosa, J. C., Hunninghake, D., Bush, D., Criqui, M. H., Getz, G. S., Gotto, A. M., Jr., et al. (1990). The cholesterol facts. Circulation, 81(5), 1721–1733.

  18. Chang, K. C.-M., Soljak, M., Lee, J. T., et al. (2016). Coverage of a national cardiovascular risk assessment program (NHS Health Check) in England. BMJ Open, 6(1), e010711.

  19. Nagpal, M. L. (Ed.). (2018). Cholesterol: Good, Bad and the Heart. BoD–Books on Demand.

  20. Budoff, M. J., Young, R., Burke, G., et al. (2018). Ten-year association of coronary artery calcium with atherosclerotic events. JACC: Cardiovascular Imaging, 11(1), 179–188.

  21. Kodama, S., Tanaka, S., Saito, K., et al. (2007). Effect of aerobic exercise training on HDL cholesterol. Archives of Internal Medicine, 167(10), 999–1008.

  22. Puri, R., Nicholls, S. J., Shao, M., et al. (2015). Coronary atheroma volume and plaque composition with intensive statin therapy. Journal of the American College of Cardiology, 65(12), 1202–1210.

  23. Casscells, W., Naghavi, M., & Willerson, J. T. (2003). Vulnerable atherosclerotic plaque: A multifocal disease. Circulation, 107(16), 2072–2075.

  24. Estruch, R., Ros, E., Salas-Salvadó, J., et al. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet (reanalysis of PREDIMED). The New England Journal of Medicine, 378(25), e34.

  25. Jenkins, D. J. A., Wong, J. M. W., Kendall, C. W. C., et al. (2011). The Portfolio diet and LDL cholesterol. JAMA, 306(8), 831–839.

  26. Brown, L., Rosner, B., Willett, W. W., & Sacks, F. M. (1999). Cholesterol-lowering effects of dietary fiber: A meta-analysis. The American Journal of Clinical Nutrition, 69(1), 30–42.

  27. Mensink, R. P., Zock, P. L., Kester, A. D. M., & Katan, M. B. (2003). Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol. The American Journal of Clinical Nutrition, 77(5), 1146–1155.

  28. Sabatine, M. S., Giugliano, R. P., Keech, A. C., et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). The New England Journal of Medicine, 376(18), 1713–1722.

  29. Schwartz, G. G., Steg, P. G., Szarek, M., et al. (2018). Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY Outcomes). The New England Journal of Medicine, 379(22), 2097–2107.

  30. Cannon, C. P., Blazing, M. A., Giugliano, R. P., et al. (2015). Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). The New England Journal of Medicine, 372(25), 2387–2397.

  31. Nissen, S. E., Lincoff, A. M., Brennan, D. M., et al. (2023). Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). The New England Journal of Medicine, 388(14), 1353–1364.

  32. Ray, K. K., Wright, R. S., Kallend, D., et al. (2020). Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol (ORION-10 and ORION-11). The New England Journal of Medicine, 382(16), 1507–1519.

  33. Brandt, E. J., Myerson, R., Perraillon, M. C., & Polonsky, T. S. (2017). Hospital admissions for myocardial infarction and stroke after trans-fatty acid restrictions in New York counties. JAMA Cardiology, 2(6), 627–634.

  34. Restrepo, B. J., & Rieger, M. (2016). Trans fat and cardiovascular mortality: Evidence from bans in Denmark. Journal of Health Economics, 45, 137–152.

  35. NCD Risk Factor Collaboration. (2020). Repositioning of the global distribution of cholesterol. Nature, 582(7810), 73–77.

  36. Stary, H. C., Chandler, A. B., Dinsmore, R. E., et al. (1995). A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 15(9), 1512–1531.

  37. Ross, R. (1999). Atherosclerosis—An inflammatory disease. The New England Journal of Medicine, 340(2), 115–126.

  38. Steinberg, D. (1989). Low density lipoprotein oxidation and atherogenesis. The New England Journal of Medicine, 320(14), 915–924.

  39. Gimbrone, M. A., & García-Cardeña, G. (2016). Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circulation Research, 118(4), 620–636.



Comments

bottom of page